Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Insurance, home therapy, and prophylaxis in U.S. youth with severe hemophilia.

Baker JR, Riske B, Voutsis M, Cutter S, Presley R.

Am J Prev Med. 2011 Dec;41(6 Suppl 4):S338-45. doi: 10.1016/j.amepre.2011.09.002.

PMID:
22099356
2.

Physical functioning in boys with hemophilia in the U.S.

Monahan PE, Baker JR, Riske B, Soucie JM.

Am J Prev Med. 2011 Dec;41(6 Suppl 4):S360-8. doi: 10.1016/j.amepre.2011.09.017.

PMID:
22099359
3.

Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia.

Soucie JM, Symons J 4th, Evatt B, Brettler D, Huszti H, Linden J; Hemophilia Surveillance System Project Investigators.

Haemophilia. 2001 Mar;7(2):198-206.

PMID:
11260280
4.

Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study.

Shapiro AD, Donfield SM, Lynn HS, Cool VA, Stehbens JA, Hunsberger SL, Tonetta S, Gomperts ED; Academic Achievement in Children with Hemophilia Study Group.

Pediatrics. 2001 Dec;108(6):E105.

PMID:
11731632
5.

Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors.

Soucie JM, Cianfrini C, Janco RL, Kulkarni R, Hambleton J, Evatt B, Forsyth A, Geraghty S, Hoots K, Abshire T, Curtis R, Forsberg A, Huszti H, Wagner M, White GC 2nd.

Blood. 2004 Apr 1;103(7):2467-73. Epub 2003 Nov 13.

6.

Self-reported barriers to hemophilia care in people with factor VIII deficiency.

Zhou ZY, Riske B, Forsberg AD, Ullman M, Baker JR, Koerper MA, Curtis RG, Lou M, Joanne W, Johnson KA.

Am J Prev Med. 2011 Dec;41(6 Suppl 4):S346-53. doi: 10.1016/j.amepre.2011.09.003.

PMID:
22099357
7.

Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators.

Soucie JM, Nuss R, Evatt B, Abdelhak A, Cowan L, Hill H, Kolakoski M, Wilber N.

Blood. 2000 Jul 15;96(2):437-42.

8.

US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization.

Baker JR, Riske B, Drake JH, Forsberg AD, Atwood R, Voutsis M, Shearer R.

Haemophilia. 2013 Jan;19(1):21-6. doi: 10.1111/j.1365-2516.2012.02915.x. Epub 2012 Jul 30.

PMID:
22845803
9.

Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.

Taki M, Shirahata A.

Haemophilia. 2009 Jan;15(1):78-82. doi: 10.1111/j.1365-2516.2008.01823.x. Epub 2008 Aug 12.

PMID:
18700841
10.

Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.

Walsh CE, Valentino LA.

Haemophilia. 2009 Sep;15(5):1014-21. doi: 10.1111/j.1365-2516.2009.02036.x. Epub 2009 Jun 1.

PMID:
19493018
11.

[Haemophilia A, B or von Willebrand disease type 3. Census of patients in the eastern part of Germany].

Scholz U, Syrbe G, Koscielny J, Klamroth R; Kompetenznetzwerk Hämorrhagische Diathesen Ost (KHDO).

Hamostaseologie. 2008;28(3):150-4. German.

PMID:
18521493
12.

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.

Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B.

Haemophilia. 1998 Jul;4(4):413-7.

PMID:
9873763
13.

Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.

Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L.

J Thromb Haemost. 2010 Jan;8(1):83-9. doi: 10.1111/j.1538-7836.2009.03650.x. Epub 2009 Oct 11.

14.

High school completion rates among men with hemophilia.

Drake JH, Soucie JM, Cutter SC, Forsberg AD, Baker JR, Riske B.

Am J Prev Med. 2010 Apr;38(4 Suppl):S489-94. doi: 10.1016/j.amepre.2009.12.024.

PMID:
20331948
15.

How to start prophylaxis.

Petrini P.

Haemophilia. 2003 May;9 Suppl 1:83-5; discussion 86-7.

PMID:
12709042
16.

Surveillance of bleeding disorders, Texas, 2007.

Mirchandani GG, Drake JH, Cook SL, Castrucci BC, Brown HS, Labaj CP.

Am J Prev Med. 2011 Dec;41(6 Suppl 4):S354-9. doi: 10.1016/j.amepre.2011.09.004.

PMID:
22099358
17.

Prophylactic factor replacement in hemophilia.

Carcao MD, Aledort L.

Blood Rev. 2004 Jun;18(2):101-13. Review.

PMID:
15010149
18.

Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data.

Zhou ZY, Wu J, Baker J, Curtis R, Forsberg A, Huszti H, Koerper M, Lou M, Miller R, Parish K, Riske B, Shapiro A, Ullman M, Johnson K.

Haemophilia. 2011 Sep;17(5):729-36. doi: 10.1111/j.1365-2516.2011.02595.x. Epub 2011 Jun 20.

PMID:
21689212
19.

A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres.

Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ.

Haemophilia. 2003 May;9 Suppl 1:19-26; discussion 26.

PMID:
12709033
20.

The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.

Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD; Association of Hemophilia Clinic Directors of Canada (AHCDC); Canadian Association of Nurses in Hemophilia Care (CANHC).

Haemophilia. 2008 Sep;14(5):923-30. doi: 10.1111/j.1365-2516.2008.01810.x. Epub 2008 Jul 14.

PMID:
18637844

Supplemental Content

Support Center